The tumor microenvironment is characterized by regulatory T cells, type II macrophages, myeloid-derived suppressor cells, and other immunosuppressive cells that promote malignant progression. Here we report the identification of a novel BDCA1
Introduction
The immunosuppressive tumor microenvironment is a major obstacle hampering the efficacy of cancer immunotherapy (1) . Not only do tumor cells express immune-inhibitory molecules like programmed cell death-1 ligands 1 and 2 (PD-L1 and PD-L2; ref.
2), but they also actively recruit immunosuppressive leukocyte populations like regulatory T cells (Treg; ref. 3) , myeloid-derived suppressor cells (MDSC; ref. 4) , and M2 macrophages (5) . This immunosuppression is not restricted to the tumor milieu, as tumor cells were shown to secrete several factors promoting the accumulation of MDSCs in peripheral tissues (6) . Altogether, these tumor-triggered immunosuppressive components prohibit effective antitumor immune responses by inhibiting dendritic cells (DC) and T-cell effector functions (7) .
Tumor-induced immunosuppression may be accountable for the low efficacy of antitumor immunotherapeutics, including DC vaccines (8, 9) . Another important determinant of the clinical success of DC vaccines, which utilize the patient's own DCs (10) , is the type, quality, and stimulation status of applied DCs (11) . Thus far, most clinical studies have been performed with ex vivo differentiated monocyte-derived DCs (MoDC). Upon activation, however, MoDCs show limited capacity to sufficiently produce T cell-polarizing cytokines and display signs of exhaustion (12) (13) (14) . Recent studies clearly demonstrated that vaccination with primary blood DCs, such as plasmacytoid DCs (pDC; ref. 15) , or BDCA1 þ DCs (16) is more efficient than MoDC vaccines in significantly enhancing overall survival of treated melanoma patients. Thus, an optimal antitumor DC vaccine can only be realized by combining the most effective DC population with strategies to neutralize tumor-promoted immunosuppression.
In the current study, we characterized a novel blood myeloid cell population that uniquely coexpresses the DC marker BDCA1 and the monocytic maker CD14. We have shown that BDCA1 
Materials and Methods

Cell isolation
Peripheral blood mononuclear cells (PBMC) were isolated from healthy donors or stage III or stage IV melanoma patients using Lymphoprep (Axis-Shield PoC AS). When indicated, the total BDCA1-expressing population (that includes BDCA1 þ DCs and BDCA1
þ CD14 þ population) was isolated from PBMCs using the BDCA1 þ DC isolation kit (Miltenyi Biotec), followed by monocyte isolation by applying MACS using anti-CD14 microbeads (Miltenyi Biotec). The two BDCA1-expressing subsets were discriminated on the basis of CD14 expression, by using anti-CD14-PerCP (BD Biosciences).
To separate BDCA1 þ DCs, BDCA1 þ CD14 þ cells, monocytes,
and MDSCs, we resorted to FACS, which was preceded by a depletion of T, B, and NK cells from PBMCs. First PBMCs were treated with an FcR blocker (Miltenyi Biotec) to avoid any aspecific binding of antibodies. Then, the PBMCs were treated with anti-CD3-FITC, anti-CD20-FITC, anti-CD56-FITC (all from BD Biosciences) and anti-CD19-FITC (Dako Cytomation) mAbs followed by treatment with anti-FITC microbeads (Miltenyi Biotec) and MACS. The depleted PBMCs were then prepared for FACS by labeling them with the following antibodies: lineage cocktail (lin1)-FITC (includes antibodies against CD3, CD19, CD20, CD56, CD14 & CD16), anti-CD14-PerCP, anti-HLA-DR-PE-Cy7 (all from BD Biosciences), and anti-BDCA1-PE (Miltenyi Biotec). The four subsets were isolated using a FACSAria II (BD Biosciences). The FACS gating strategy is displayed in Supplementary  Fig. S1 . Na€ ve CD4 þ T-cell population was isolated from PBMCs by first isolating the total CD4 þ T-cell population using MACS CD4 þ T cell isolation kit (Miltenyi Biotec). Subsequently, na€ ve
þ T cells were separated from memory T cells by applying anti-CD45RO-PE (Dako Cytomation) and anti-PE beads (Miltenyi Biotec) followed by MACS. Purity levels higher than 98% were achieved, determined by flow cytometry.
Ascites material
Ascites were collected from patients suffering from stage III or IV epithelial ovarian cancer of serous histology. Ascites was filtered over a 100-mm cell strainer (BD Biosciences) before separating mononuclear cells by centrifuging over a density gradient. To determine the percentages of BDCA1 þ DCs and BDCA1 þ CD14 þ cells in the ascites, the isolated mononuclear cells were stained with anti-CD45-FITC, anti-BDCA1-PE, anti-BDCA3-APC (all from Miltenyi Biotec), anti-CD19-PerCP, anti-CD16-PE-Cy7, and anti-CD14-APC (all from BD Biosciences) mAbs. Cells were acquired on a CyAnTM ADP flow cytometer (Beckman Coulter). All flow cytometry data in this study were analyzed using FlowJo software (Tree Star).
Phenotype
The phenotype of BDCA1 þ DCs, BDCA1 þ CD14 þ cells, and monocytes was compared by flow cytometry. The following antibodies were used to determine the phenotype: anti-CD1a-FITC (Biolegend), anti-HLA-DR-PE-Cy7, anti-CD11c-PE, anti-CD33-APC, anti-CD206-FITC (both from BD Biosciences), anti-CD16-APC (Miltenyi Biotec), and anti-CD209-PE (Beckman Coulter). Flow cytometry was performed using either FACSCalibur or FACS Verse (both from BD Biosciences).
Uptake assay
The antigen uptake capacity of BDCA1 þ DCs, BDCA1 
Cellular subset activation
After isolation, the cellular subsets were cultured in a roundbottom 96 well-plate (50 Â 10 3 cells for cytokine detection and 10 Â 10 3 for coculture with T cells) using X-VIVO 15 medium supplemented with 5% human serum (HS; Bloodbank Rivierenland). These cells were either left unstimulated or they were stimulated with 450 U/mL GM-CSF (CellGenix), Pam3CSK4 (10 mg/mL; EMC), 1 mg/mL lipopolysaccharide (LPS), 20 mg/mL pIC (both from Sigma-Aldrich), or a mix of 20 mg/mL pIC and 4 mg/mL R848 (Axxora), and incubated overnight at 37
C. The expression of costimulatory molecules after activation was determined using anti-CD80-APC and anti-CD86-APC (both from BD Biosciences) mAbs. Cytokine production by these subsets was determined by measuring IL6 (Sanquin Reagents), IL12 (Thermo Fisher Scientific), TNFa (BD Biosciences), and IL10 (eBioscience) using a standard sandwich ELISA in 24-hour supernatants.
Mixed lymphocyte reaction
The ability of the subsets to induce T-cell proliferation and cytokine production was tested in a mixed lymphocyte reaction (MLR). A total of 1 Â 10 4 of unstimulated or stimulated cells (as above) were added to 1 Â 10 5 freshly isolated allogeneic nonadherent peripheral blood lymphocytes (PBL) from a healthy donor. IFNg and IL10 production by those T cells was determined in 48- Supplementary Fig. S2 for determination of this cutoff) for at least one subset in all three donors were taken into account. Missing values were replaced by the lowest overall RPKM value obtained in the whole study. On the basis of RPKM values for each gene the expression in each cell type with respect to the donor mean of all three cell types was calculated to obtain relative values that were subsequently log2 transformed. RNA sequencing data are deposited at the Gene Expression Omnibus (GEO; accession number GSE75042).
Hierarchical clustering and principal component analysis
Relative log-transformed data were used as input for hierarchical clustering and principal component analysis (PCA). Similarity matrices and hierarchical clustering for specific gene sets were generated using Euclidian distance in GENE-E software using standard settings (Broad Institute, Cambridge, MA; http://www.broadinstitute.org/cancer/software/GENE-E/index. html). PCA analysis was performed in the MEV(4.9.0) software environment (http://www.tm4.org/mev.html), as described previously (18) .
Gene-set enrichment analysis
De novo gene sets were generated for inflammatory DCs (infDCs) and CD14 þ monocytes from processed and normalized microarray data, downloaded from the Gene Expression Omnibus website (GSE40484; http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc¼GSE40484), and used as input for a 3-group ANOVA in the MEV(4.9.0) software environment. Differentially expressed genes (DEG) between groups (P < 0.05 after applying a Bonferroni correction for multiple testing) were assigned post hoc to a gene set for a particular cell type if the mean expression exceeded that of the other two cell types. In addition, we used the MoDC signature and BDCA1 þ DC signature gene sets as previously generated by Segura and colleagues (19) . The detailed composition of all these gene sets, as well as the possible overlap between them, is provided in Supplementary Data 1 and Supplementary Fig. S3 , respectively. An irrelevant collection of gene sets (the C2 gene set from mSig database; http://software.broadinstitute.org/gsea/msigdb/collections.jsp#C2) was used in addition to the four test gene sets to evaluate the Normalized Enrichment Scores (NES) and the false discovery rate (FDR) more properly. These gene sets were used as input for a Gene Set Enrichment analysis (GSEA), using the GSEA webtool version 2.2.1 (http:// www.broadinstitute.org/gsea/index.jsp; refs. 20, 21) . Genes were ranked by taking 2log expression ratios of classes, and enriched signatures were calculated using the weighted statistic. A minimum presence in the RNAseq data of 5 and a maximum of 500 genes was required for each gene set. A 1,000 permutations per gene set were performed. The GSEA analysis was visualized using Bubble GUM software (http://www.ciml.univ-mrs.fr/applications/BubbleGUM/index.html; ref. 22) .
Multiplex (antibody microarray) analysis
To analyze the differential expression of CD markers and other relevant proteins among BDCA1 þ DCs, BDCA1 þ CD14 þ cells and monocytes these subsets were isolated as described above. The cells were washed, frozen, and sent to Sciomics GmbH for further analysis. In short, proteins were extracted by adding Scio-Extract buffer (Sciomics), quantified, and labeled with fluorescent dyes. All samples were analyzed in a reference-based dual color approach on Scio-CD Antibody microarrays (Sciomics) targeting 81 CD-marker as well as additional relevant cytokines, chemokines, and other proteins (Supplementary Table S1 ). Each antibody is represented in six replicates on the array. The arrays were blocked and each sample was incubated competitively with a reference sample on one array. Resulting data were analyzed using the linear models for microarray data (LIMMA) package of RBioconductor after uploading the mean signal intensities for differential protein expression.
Immunofluorescence staining
Immunofluorescence staining was performed on 4-mm thick sections of paraffin-embedded resection specimens of healthy skin, skin and colon lesions of metastatic melanoma, and draining lymph nodes. Slides were dried overnight at 37 C. Next, they were deparaffinized in xylene, followed by graded alcohols and finally tap water. Heat-induced antigen retrieval was performed in 10 mmol/L citrate acid buffer (pH 6.0) by microwaving for 15 minutes after boiling. Blocking was performed with 1% BSA in TBST for 10 minutes at room temperature. Samples were stained by Opal TSA Plus multiplex tissue staining kits (Perkin Elmer) according to the standard protocol provided. Slides were subsequently stained with mouse anti-CD14 (IgG 2a , Leica Biosystems) labeled with Cyanine 5 fluorophore, mouse anti-HLA-DR (IgG 2b , Thermo Fisher Scientific) labeled with Cyanine 3 fluorophore, mouse anti-CD1c (BDCA1, IgG 1 , Abcam) labeled with fluorescein, and a cocktail to identify tumor cells (melanoma mix) consisting of mouse anti-HMB45 (IgG 1 , Dako), mouse anti-Mart-1 (IgG 1 , Thermo Immunologic), mouse anti-Tyrosinase (IgG 2a , Monosan), and rabbit anti-SOX-10 (IgG, Cell Marque) labeled with Cyanine 3.5. BrightVision poly-HRP-anti Ms/Rb/Rt IgG (Immunologic BV) was used for the secondary antibody incubations. Finally, slides were counterstained and mounted using DAPI Fluoromount-G (Southern Biotechnology Associates, Inc). Whole slide multispectral scan was performed using the Vectra slide scanner (version 2.0.7; PerkinElmer). Multispectral images were unmixed using spectral libraries built from images of single stained tissues for each reagent and unstained tissue using inForm (version 2.1.1; PerkinElmer). A selection of 20 to 30 representative original multispectral images of the particular tissue type (skin, colon, or lymph node) were used to train inForm for quantitative image analysis; segmentation of tumor/stromal tissue based on cyanine 3.5 signal, cell segmentation based on DAPI and membrane stain signals (HLA-DR, CD14 and BDCA1), and finally phenotyping of different cell types. All settings applied to the training images were saved within an algorithm. Vectra Review (Version 2.0.8, PerkinElmer Inc.) was used to select the areas for analysis; this consisted of the tumor and stromal tissue around it or all stromal tissue of control tissues. Batch analysis of the tumor and control tissues was performed with the same algorithm but separate algorithms were generated between tissue types.
Morphologic analysis
FACS-sorted cells were subjected to cytospin and stained with May-Gr€ unwald/Giemsa. In short, slides were fixed in methanol for 10 minutes and stained with May-Gr€ unwald (Merck) for 5 minutes, washed, and stained with Giemsa (Merck) for 15 minutes, respectively. Pictures were taken with a Leica DM6000 B microscope equipped with a Leica DFC 480 camera (63Â objective), using Leica Application suite V4.3.0.
Statistical analysis
Student t tests were performed for paired measurements with GraphPad Prism software (GraphPad La Jolla, CA). Values of P < 0.05 were considered significant.
þ cell population is associated with lower
In a recent clinical trial performed by our group, BDCA1 þ DC vaccines were utilized to treat melanoma patients (16 Tumors are infiltrated by cells resembling the blood BDCA1
To determine whether progressive tumors may have an influence on BDCA1 þ CD14 þ cell counts in the circulation, the frequency of this population was assessed in the peripheral blood of stage III/IV melanoma patients and healthy donors by flow cytometry (Supplementary Fig. S1 ). Interestingly, we noticed that the frequency of BDCA1 þ CD14 þ cells was significantly elevated in melanoma patients in comparison with healthy donors ( Fig. 2A ). This increase concurred with an already reported rise in circulating MDSCs (24, 25) . Also, a trend of lower BDCA1 þ DC frequency was observed in melanoma patients ( Fig. 2A) . Cells coexpressing CD14 and BDCA1 were also detected in metastatic melanoma lesions from skin, their draining lymph nodes, and from colon metastases (Fig. 2B) . Interestingly, the melanoma skin metastatic lesions contained significantly higher numbers of
) cells in comparison with healthy skin, whereas the numbers of BDCA1 þ cells (Fig. 2C ). There was a tendency of increased numbers of those three populations in metastatic melanoma lesions (lymph nodes and colon), in comparison with healthy tissues (Supplementary Fig. S5 ). Moreover, BDCA1
þ CD14 þ cells were also detected in inflammatory tumor ascites from ovarian cancer patients, where they were even significantly more abundant than BDCA1 þ cells (Fig. 2D) , as previously reported (19) . Although the existence of a CD14 þ DC subset has been described in the skin dermis (26) , in the synovial fluid of inflamed arthritic joints and in ascites from breast or ovarian cancer patients (19) , such a population has never been investigated in blood or in relation to melanoma. Therefore, we first analyzed the morphology of BDCA1 also expressed the monocytic marker CD11b at higher levels than BDCA1 þ DCs, yet lower than monocytes (Fig. 2F) . Moreover, the BDCA1 þ CD14 þ population lacked CD16 expression that is characteristic for a subset of nonclassical monocytes (27) and a CD16 þ subset of DCs (28) . All three populations shared high expression of the myeloid marker CD33, and virtually lacked CD1a, CD209, and CD206 expression (Fig. 2F) (Fig. 3C) . However, the expression of antigen-presenting class II HLA molecules and CD1 molecules was similar to that of BDCA1 þ DCs (Fig.   3C ). Taken together, these data further support the notion that BDCA1 þ CD14 þ cells form a distinct population with a unique gene expression profile. Recently, Segura and colleagues (19) described the presence of an inflammatory DC (infDC) resembling in vitro-generated moDCs in inflammatory fluids. To find out whether the BDCA1 þ CD14 þ cells are homologous to these inflammatory cells, we performed a gene-set Enrichment analysis (GSEA). We retrieved three signatures described in Segura and colleagues for moDCs, BDCA1 þ DCs, and monocytes. In addition, because a ready-to-use signature for the infDCs was lacking, we generated a gene set for these cells using the published microarray data. In parallel, we also generated gene sets for monocytes and BDCA1 þ DCs from these data. Together, this yielded 6 gene sets (3 preexisting and 3 newly generated signatures). Unfortunately, 2 gene sets (the existing monocyte signature and the newly generated BDCA1 þ DC high set) were not covered in our RNA sequencing data with more than 5 genes and thus excluded. The remaining 4 sets were analyzed with GSEA ( 
CD14
þ cells clustering closer to monocytes (Fig. 3E) . Thus, protein analysis further supports the uniqueness of the BDCA1 þ CD14 þ population. 
þ cells displayed a significantly higher uptake of fluorescently labeled BSA, which was already apparent after 15 minutes of incubation (Fig. 4A, left) . Monocytes were the best in antigen uptake, although the differences between BDCA1 þ CD14 þ cells and monocytes were insignificant (Fig. 4A, right) . A major hallmark of DCs is their ability to sense danger signals and to respond by expressing costimulatory molecules and secreting cytokines, a process also referred to as maturation (32) . Therefore, we determined to what extent BDCA1 þ CD14 þ cells can mature in response to LPS (a TLR4 ligand) and pIC (a TLR3 ligand). In addition, we stimulated cells with GM-CSF, commonly used in cancer immunotherapy. BDCA1
þ DCs responded to both LPS and pIC by upregulating the costimulatory molecules CD86 and CD80. BDCA1 þ CD14 þ cells also responded to both stimuli, yet surprisingly only upregulated CD80 expression. Monocytes on the other hand modestly upregulated CD80 expression only in response to LPS and less efficiently than the other two subsets (Fig. 4B) 
þ cells were superior in producing the anti-inflammatory cytokine IL10 (Fig. 4C ). This cytokine production profile was similar upon triggering TLR2 and TLR8 by Pam3CSK4 and R848, respectively ( Supplementary Fig. S8 ). As for IL12 secretion, characteristic for BDCA1 þ DCs, it was lacking in the two other subsets (Supplementary Fig. S9 ). Collectively, BDCA1 
þ cells to induce PBL proliferation was higher than that of monocytes and lower than that of BDCA1 þ DCs, regardless of the type of treatment (Fig. 5A ).
The levels of IFNg in the supernatant of MLR cultures containing LPS-stimulated BDCA1 þ CD14 þ cells were low in comparison with BDCA1 þ DCs, yet increased to similar levels after pIC stimulation. On the other hand, IL10 was produced at comparable levels by PBLs stimulated by any of the cellular subsets, although pIC-stimulated monocytes triggered lower IL10 production by PBLs in comparison with BDCA1 þ DCs and BDCA1 þ CD14 þ cells (Fig. 5A) .
In a more refined setting, we determined their capacity to induce the proliferation of allogenic na€ ve CD4 þ T cells. Similar to the MLR setting, BDCA1 þ CD14 þ cells were better at inducing CD4 þ T-cell proliferation than monocytes, but lesser than BDCA1 þ DCs (Fig. 5B) . To determine the T-cell polarizing capacity of the three subsets, na€ ve CD4 þ T cells were used. To our surprise, BDCA1 and newly generated gene sets of genes highly expressed in either infDCs or monocytes were used as input for GSEA and visulaized by Bubble Gum. As indicated in the table legend, circle area represents the normalized enrichment scores (NES), and color intensity represents the false discovery rate (FDR). Transcriptome and multiplex analyses of BDCA1
þ cells, and monocytes was performed by sequencing the whole RNA of these cells that were isolated from peripheral blood of three healthy donors. A, the relation between these subsets was determined by a similarity matrix based on the Euclidian distance between the samples (left) and by visulaizing the distribution of the subsets in the space defined by the two principal components accounting for the majority of variation in the data (right). The three subsets were also clustered on the basis of the differential expression of myeloid lineage-specific transcription factors (B) and growth factor receptors (C), toll-like receptors, C-type lectins, Fc receptors or CD1 and HLA molecules. D, hierarchical clustering of RNA sequencing data based on the gene sets used in Table 1 . E, hierarchical clustering based on multiplex data of the three subsets, obtained from three donors. Log ratios were subjected to complete linkage hierarchical clustering using an Euclidean distance metric.
T cells. This was accompanied by a higher induction of IL4-producing T cells (Supplementary Fig. S10A ). To reveal whether BDCA1 þ CD14 þ cells are capable of inducing IL17-producing CD4 þ T cells, we applied the same experimental setup described by Segura and colleagues (19) . In this setup, BDCA1 þ CD14 þ cells,
BDCA1
þ DCs, and monocytes that were isolated from the peripheral blood of melanoma patients failed to induce noteworthy amounts of IL17-secreting CD4 þ T cells (Supplementary Fig.   S10B ). Thus, BDCA1 
The observed differences in T-cell stimulatory capacity between BDCA1
þ DCs and BDCA1 þ CD14 þ cells could be attributed to the lower expression of costimulatory molecules that are vital for T-cell activation (Fig. 4B ), but could also be mediated through coinhibitory molecules (33), such as PD-L1 and PD-L2. We did not detect PD-L2 expression on any of the subsets, with or without stimulation (data not shown). PD-L1, however, was expressed at higher levels by BDCA1 Fig. S11 ). Interestingly, blocking PD-L1 in the KLH-specific suppressor assay did not reverse the observed suppressive effect exerted by BDCA1 Supplementary Fig. S12 ). Thus, these results demonstrate that a higher PD-L1 expression by BDCA1 þ CD14 þ cells plays a role in hampering the functionality of this cell population.
Systemic cancer-induced factors drive the differentiation of monocytes and BDCA1
The conspicuous increase in the percentage of circulating BDCA1 þ CD14 þ cells in melanoma patients ( Fig. 2A) suggests that tumor-associated factors could invoke the emergence of this population from another precursor population. Monocytes are well known for their plasticity and capacity to differentiate into several cellular types, and may therefore be the most plausible candidate as the ancestral population of BDCA1 þ CD14 þ cells. We tested this hypothesis by culturing monocytes, isolated from the peripheral blood of healthy donors, in the presence of melanoma patientderived serum. Monocytes cultured in serum obtained from healthy individuals did not express any BDCA1, whereas, and in line with our hypothesis, melanoma patient-derived serum readily stimulated the expression of BDCA1 on the cultured monocytes (Fig. 6A ). Similar to BDCA1 þ CD14 þ cells found in melanoma patient blood, the ex vivo-generated cells also displayed reduced autofluorescence (tinted histograms) and maintained the expression of CD14. The serum of the melanoma patients also increased CD11c and HLA-DR expression, thus leading to a cell surface profile similar to that of primary BDCA1 þ CD14 þ cells isolated from circulation. Interestingly, using the same setup with BDCA1 þ DCs Figure 5 . instead of monocytes, similar results were obtained with a subpopulation clearly coexpressing BDCA1 and CD14 (Fig. 6B) 
Discussion
Tumor-induced immunosuppression is the Achilles heel of both naturally arising immune responses and responses induced by anticancer immunotherapeutics. Tumors can suppress at many levels. They have been suggested to disrupt chemokine circuits that are pivotal for T-cell attraction (34, 35) , can manipulate vascular endothelium to form a physical barrier in the face of tumor-reactive T cells (36) , and can actively suppress these cells (37) . Once T cells manage to transmigrate through the endothelial barrier, they have to negotiate a hostile immunosuppressive tumor stroma before encountering tumor cells. Tumors recruit and promote the expansion of immunosuppressive leukocyte populations like Treg cells (3), MDSCs (4), and M2 macrophages (5 Transcriptome analysis revealed a possible relation between BDCA1 þ CD14 þ cells and macrophages as demonstrated by the expression of genes that are pivotal for macrophage differentiation in mice, such as CSF1R (29) . Nevertheless, CSF1R was also reported to be highly expressed by infDCs in both mice (39) and humans (19) . Macrophages are by definition tissue-resident cells, whereas BDCA1 þ CD14 þ cells are found in both circulation and tissues, highlighting another discrepancy between the two cell subsets and arguing against classifying them in the same group. Yet the similarities revealed by transcriptome data urge for further delineation of the link between these two subsets. CD14 expression is not restricted to monocytes. Also, DCs in certain compartments or under certain conditions express CD14. Indeed, steady-state human dermis harbors a CD14 Tumor-associated immune suppression functions in part through immune-inhibitory molecules that sabotage tumor-specific immune responses. Among these inhibitory molecules is the PD-1/PD-L1 pathway. High PD-L1 expression levels by tumor cells, tumor-infiltrating lymphocytes, or both, are associated with aggressive tumor behavior, poor prognosis, and elevated risk of mortality (2) . Interestingly, the PD-L1/PD-1 checkpoint can be targeted by several clinical-grade antibodies currently being tested. Thus far, clinical trials targeting PD-1 (49, 50) or PD-L1 (51) by blocking antibodies not only proved tolerable, but showed durable antitumor responses in up to 50% of all treated melanoma patients. In this respect, checkpoint inhibitors may act on PD-L1 expressed by both tumor cells and BDCA1 þ
CD14
þ cells.
Collectively, we characterized a novel cell subset, which may contribute to the systemic state of immunosuppression in cancer patients, and thus impairing the efficacy of cancer immunotherapy. Thus, a direct opportunity to enhance the efficacy of DC vaccination lies in the depletion of BDCA1 þ DC-based vaccines of suppressive BDCA1 þ CD14 þ cells and systemically annihilating the suppressive functions of this population.
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